TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

Only a minority of myelodysplastic syndrome (MDS) patients respond to hypomethylating agents (HMAs), but strong predictors of response are unknown. We sequenced 40 recurrently mutated myeloid malignancy genes in tumor DNA from 213 MDS patients collected before treatment with azacitidine (AZA) or dec...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Bejar, Rafael, Lord, Allegra, Stevenson, Kristen, Bar-Natan, Michal, Pérez-Ladaga, Albert, Zaneveld, Jacques, Wang, Hui, Caughey, Bennett, Stojanov, Petar, Getz, Gad, Garcia-Manero, Guillermo, Kantarjian, Hagop, Chen, Rui, Stone, Richard M., Neuberg, Donna, Steensma, David P., Ebert, Benjamin L.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2014
Pynciau:
Myeloid Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4208285/
https://ncbi.nlm.nih.gov/pubmed/25224413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-06-582809
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg